Jon E Grant1, Sarah A Redden1, Gustavo C Medeiros1,2, Brian L Odlaug3,4, Erin E Curley5, Hermano Tavares2, Nancy J Keuthen5. 1. a Department of Psychiatry & Behavioral Neuroscience , Pritzker School of Medicine, University of Chicago , Chicago , IL , USA. 2. b Department of Psychiatry , University of Sao Paulo , Sao Paulo , Brazil. 3. c Faculty of Health and Medical Sciences , University of Copenhagen , Copenhagen , Denmark. 4. d H. Lundbeck A/S , Valby , Denmark. 5. e Department of Psychiatry , Massachusetts General Hospital/Harvard Medical School , Boston , MA , USA.
Abstract
OBJECTIVE: Trichotillomania (TTM) is associated with high rates of co-occurring depression and anxiety disorders. What the co-occurrence of TTM, depression or anxiety disorders means clinically and cognitively, however, has garnered little research attention. METHODS: About 530 adults with TTM were examined on a variety of clinical measures including symptom severity, psychosocial measures of functioning, psychiatric comorbidity and neurocognitive testing assessing motor inhibition and cognitive flexibility. Clinical features and cognitive functioning were compared between TTM patients with current comorbid major depressive disorder (MDD), a current anxiety disorder, both MDD and an anxiety disorder, or neither. RESULTS: Of 530 participants, 58 (10.3%) had MDD only, 97 (18.3%) had an anxiety disorder only, 58 (10.3%) had both MDD and an anxiety disorder, and 317 (59.8%) had neither. For almost all clinical measures, those with MDD only reported worse symptoms than those with an anxiety disorder only, and the combination of MDD and an anxiety disorder reported the worst level of symptom severity. CONCLUSIONS: These results suggest that adults with TTM and co-occurring MDD and anxiety disorders exhibit unique clinical differences. The clinical differences may also have treatment implications.
OBJECTIVE:Trichotillomania (TTM) is associated with high rates of co-occurring depression and anxiety disorders. What the co-occurrence of TTM, depression or anxiety disorders means clinically and cognitively, however, has garnered little research attention. METHODS: About 530 adults with TTM were examined on a variety of clinical measures including symptom severity, psychosocial measures of functioning, psychiatric comorbidity and neurocognitive testing assessing motor inhibition and cognitive flexibility. Clinical features and cognitive functioning were compared between TTM patients with current comorbid major depressive disorder (MDD), a current anxiety disorder, both MDD and an anxiety disorder, or neither. RESULTS: Of 530 participants, 58 (10.3%) had MDD only, 97 (18.3%) had an anxiety disorder only, 58 (10.3%) had both MDD and an anxiety disorder, and 317 (59.8%) had neither. For almost all clinical measures, those with MDD only reported worse symptoms than those with an anxiety disorder only, and the combination of MDD and an anxiety disorder reported the worst level of symptom severity. CONCLUSIONS: These results suggest that adults with TTM and co-occurring MDD and anxiety disorders exhibit unique clinical differences. The clinical differences may also have treatment implications.
Authors: Sydney D Biscarri Clark; Ashley A Lahoud; Theresa R Gladstone; Emily P Wilton; Christopher A Flessner Journal: Child Psychiatry Hum Dev Date: 2022-03-21
Authors: Christine Lochner; Nancy J Keuthen; Erin E Curley; Esther S Tung; Sarah A Redden; Emily J Ricketts; Christopher C Bauer; Douglas W Woods; Jon E Grant; Dan J Stein Journal: Brain Behav Date: 2019-11-06 Impact factor: 2.708